Generics

Controversial Study Raises Alarm Over Safety of Indian Generic Drugs in the U.S.

22 days ago

A recent study alleging potential safety risks associated with Indian generic drugs has ignited intense debate and backlash within both the pharmaceutical industry and healthcare sectors in the United States. The research, which has stirred fears among patients and healthcare professionals, claims that certain medications produced in India may not meet the stringent safety standards expected in Western markets.

Weight Loss Medication Market Faces Disruption Amid Rising Competition

24 days ago

Recent developments in the weight loss medication market have sparked notable changes as emerging alternatives to popular drugs like Wegovy and Zepbound begin to surface. These new contenders are now exerting pressure on existing players, leading to a significant shift in dynamics within this rapidly evolving sector.

Zepbound Manufacturer Cuts Costs to Compete with Generic Rivals

1 month ago

In a strategic move to counter the growing threat of cheaper generic alternatives, the manufacturer of Zepbound, a medication designed to treat a range of conditions, has announced significant price reductions on its vials. This decision comes as the pharmaceutical landscape becomes increasingly competitive, with generic versions of Zepbound seeking to capture market share.

Chinese Health Watchdog Stands Firm on Quality of Domestic Generic Drugs Amid Rising Concerns

2 months ago

The Chinese National Medical Products Administration (NMPA) has recently issued a strong defense regarding the quality standards of local generic medications. This statement comes in light of growing scrutiny and skepticism towards the efficacy and safety of domestically produced pharmaceuticals. The regulatory body emphasized that ongoing rigorous quality control measures are in place to ensure that generic drugs meet international standards.

Insights from Sandoz CEO Richard Saynor on Ozempic, Big Pharma Struggles, and Political Influences

3 months ago

In a candid conversation, Richard Saynor, CEO of Sandoz, provided a deep dive into the complexities surrounding the pharmaceutical landscape, including the rising prominence of Ozempic, challenges facing the industry, and the influence of political figures such as Donald Trump. Saynor’s insights shed light on the evolving narratives within Big Pharma and the implications for patients, healthcare, and future drug development.